key: cord-0835385-ed6skftj
authors: Cakir, Banu
title: Convalescent Plasma (CP) Therapy in Patients with COVID-19
date: 2020-11-19
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2020.103018
sha: 41f65121d3e61a5edd5237c90cdee62d5ed79af0
doc_id: 835385
cord_uid: ed6skftj

nan

The published work is valuable regarding its sample size, representativeness of patients treated by CP transfusion and having a comparable control group.

Unfortunately, the potential for biases and confounders cannot be discarded, and statistical analysis could have been advanced to provide better evidence for the readers. As an epidemiologist, I would like to raise concern regarding its limitations and more importantly to guide the readers (potential authors of similar work) to collect and analyze further data (on dosing, timing, number of CP transfusions, and on how vital to detect/report the neutralizing antibody content of CPs used are) for providing concrete evidence on potential of CP transfusions in treating COVID-19 patients.

We have read with great interest the paper recently published in your journal by Altuntas et al., entitled "Convalescent Plasma (CP) Therapy in Patients with COVID-19". Studies on effectiveness and safety of CP therapy against SARS-CoV-2 infection is of great concern to clinicians treating COVID-19 patients, given the absence of any authorized effective medication or vaccine at present. Although scarce in number and mainly descriptive, recent studies have suggested safe use of CP, with some improvement in clinical characteristics of the patients and some benefits to the health care delivery [1] [2] [3] .

We congratulate the authors to conduct a retrospective cohort study of all severe and critically ill COVID-19 patients based on electronic records of the Turkish Ministry of Health. The study included all 888 patients with the exposure (CP transfusion) and selected a subsample of those unexposed (n= 888), matched to cases on potential confounders including age, gender, comorbidity and the antiviral treatments used [4] . Having a comparable control group was the main asset of the study design, however, information was missing on: 1) the total number of severe and critically ill patients (target population); 2) total number of eligibles with matched characteristics and whether a representative sampling strategy was used for reaching the final "unexposed" group. Thus, the potential for a selection bias cannot be excluded.

Potential for confounding cannot be excluded [5] . Anti-SARS-CoV-2 antibody-containing CP was found to be significantly and negatively associated with the length of intensive care unit stay, need for mechanic ventilation and need for vasopressor state, yet the case-fatality rate (CFR) was not significantly lower (24.7% vs. 27.7%). We wonder whether the non-significant effect of CP on CFR could be explained, at least partially, by "confounding by indication" [6] , as a result of J o u r n a l P r e -p r o o f prescribing CP to patients based on physicians' expectation of a worse outcome in these patients due to factors other than those matched on (Table 1) [4] , such as levels of infection-related biomarkers or inflammatory cytokines. It is also of concern, whether the use of steroids and/or anticoagulants was similar in patients across the groups. It is not clear whether all hospitals in the country had the capacity to use CP for their patients or only selected hospitals could provide it. If so, it is important to either match on those hospitals or adjust for it in CFR calculations. It could be likely that the care standards might be different across hospitals using CP. Such a variation might have confounded the associations studied with potential outcomes presented in Table 2 [4] .

Onset of symptoms is more prone to information (recall/awareness) bias [7] , thus, we assume that authors presented Tables 3 and 4 together [4] . Both tables suggest that effect of CP is more prominent on severity of disease rather than fatality, and it is obvious that time from onset of disease is a significant modifier of effect of CP on clinical status of the clinical/severe COVID-19 patients; with, the lag between symptoms and diagnosis appear to vary across the time periods chosen. Given that the sample size is sufficient, we believe that it would be more appropriate to present the "time effect", studying adjusted hazard ratios, or at least incidence rate ratios, instead of presenting of cumulative incidence rates (Tables 3 and 4 

It is noteworthy that data on pathogen inactivation processes and anti-SARS-CoV-2 IgG antibodies screenings were not completed [4] . Pathogen inactivation of plasma is shown [8] not to alter the potential therapeutic potency of CP, and is highly desirable in all cases regarding the currently unproven clinical risk-to-benefit ratio of CP and concern about possible super infections with SARS-CoV-2, besides J o u r n a l P r e -p r o o f controlling the residual risk for other transfusion-transmitted infectious diseases [9] [10] .

Given increasing rates of COVID-19-related mortality and morbidity globally, CP transfusion appears to be a valuable and widely available candidate for intervention. Safe collection and proper use of CP should be motivated with concurrent monitoring and reporting of patient outcomes [11] . Randomized clinical trials provide higher quality of evidence, yet, will require time in an evolving pandemic. Well-planned prospective cohort studies of routine CP use in various clinics can provide high quality evidence upon proper control of confounders and efficient explanation of effect modifiers. Thus, we encourage clinicians to record detailed information on exact transfusion time, doses, number of repeated transfusions and interval(s) between those. It is strongly recommended that SARS-CoV-2 total antibodies or neutralizing antibody titers be measured in the specimen obtained from a donor before donation or from donated plasma-after donation or after processing [10] . Otherwise, a dose-response association (if any) cannot be investigated in analyses. Lastly, but not the least, it is important to keep tract of transfusion-related adverse effects (if any), which may be of greater concern as the frequency of CP use increase over the course of evolving pandemic.

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Treatment of 5 Critically Ill Patients with COVID-19 With Convalescent Plasma

The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

Convalescent Plasma Therapy in Patients with COVID-19. Transfusion and Apheresis Science. 2020

Do not get confused by the confounders: identification and control of confounders in medical research

Catalogue of bias collaboration

Bias in medical research: types, classification, sources, and control measures: Review-I Türkiye Klinikleri Tıp Bilimleri Dergisi

Stability and neutralizing capacity of SARS-CoV-2-specific antibodies in convalescent plasma

Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma

European Commission Directorate-General for Health and Safety. An EU programme for COVID-19 convalescent plasma collection and transfusion. Guidance on collection, testing, processing, storage, distribution and monitored use

Convalescent plasma as potential therapy for COVID-19